Key facts
- Deftbiotech’s last known valuation is $6.4M (Mar 2026).
- It has raised $710K; the latest was Seed Round ($710K) in Mar 2026.
- Notable investors include Breakthrough Victoria, La Trobe University.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Deftbiotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Deftbiotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Deftbiotech
Developer of antifungal therapeutic agents designed for the treatment of human skin and nail infections. The company is advancing a novel peptide-based compound from the plant defensin family that rapidly eliminates multiple fungal pathogens through a different mechanism from existing treatments, enabling healthcare providers and patients to access effective treatment for onychomycosis and related conditions.
- Sector
- Healthcare
- HQ
- Melbourne, Australia
- Ownership
- Privately Held (backing)
Deftbiotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Deftbiotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Deftbiotech in its N-PORT filings yet. We sweep new filings monthly.